HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Poor Results For Supplementation To Curb Depression In First-Of-Kind Study

Executive Summary

Supplementation with omega-3s, folic acid, vitamin D3, calcium and selenium did not reduce MDD onset in overweight subjects with history of depression, according to first RCT on effectiveness of two nutritional strategies and their combination in preventing depression among high-risk subjects.

You may also be interested in...

Vitamin D Benefits Don’t Extend To Preventing Depression In Older Adults – Study

Vitamin D3 intake didn’t prevent depression among consumers 50 and up, according to results of a five-year study published in the Journal of the American Medical Association. The research was among first studies “statistically powered” to answer long-standing question on vitamin’s benefit on mood.

US Wellness Market In 2019: Amarin Wins, Loses On Supplements; Gottlieb Leaves With Consumer Health Flourish

Looking look back on US wellness market developments and events in 2019, HBW Insight finds a firm that doesn’t compete in the dietary supplement sector, Amarin, made a good bit of news that affected the industry during the year. We track news across the wellness space from the past year.

Second Warning, Second Unsafe Ingredient For Total Body Nutrition

FDA's Sept. 28 warning letter to Total Body Nutrition also noted violative claims and labeling for its products marketed with the TBN brand and listed GMP problems. First methylsynephrine in 2016, now DMAA land firm on FDA enforcement radar.

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts